Katrine Bosley | Chief Executive Officer
Editas Medicine

Katrine Bosley, Chief Executive Officer, Editas Medicine

Katrine joined Editas Medicine as President and CEO in June 2014. Before Editas, Katrine was the CEO of Avila Therapeutics (acquired by Celgene), a biopharmaceutical company that pioneered a class of medicines known as targeted covalent drugs, from May 2009 to March 2012. After the acquisition of Avila by Celgene, Katrine served as President, Celgene Avilomics Research at Celgene from March to May of 2012. She was also recently the Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, from September 2013 to May 2014. Earlier, she was VP, Business Development at Adnexus Therapeutics and then VP, Strategic Operations after its acquisition by Bristol-Myers Squibb. Prior to that, at Biogen Idec, Katrine held roles in business development, commercial operations and portfolio strategy in the U.S. and Europe and led numerous transactions there, including the alliance for Tysabri® (natalizumab), a treatment for multiple sclerosis. Katrine was also part of the healthcare team at the venture firm Highland Capital Partners and was an early employee of Alkermes. Katrine is a graduate of Cornell University.

In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA), is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG) and of Scholar Rock, LLC. Katrine also serves on the board of directors of the Biotechnology Industry Organization and is a review committee member for the Translation Fund of the Wellcome Trust.

Appearances:



World Orphan Drug Congress USA 2018 - Conference Day Two (General) @ 09:00

Keynote address: Advancing innovative therapies to treat genetically-defined diseases using CRISPR-based genome editing

  • Momentum toward making medicines – a potentially transformative new category of medicines that aim to repair “broken” genes
  • Strategy focused on diseases with few or no available treatments and exploring a Regulatory framework for CRISPR-based medicines
  • New data demonstrating advancements for translating CRISPR technologies into medicines
  • Clinical natural history study of Leber Congenital Amaurosis to understand the disease course and potential clinical endpoints 
  • Advancing toward the clinic with potential to transform therapy for retinal disease LCA10-CEP290 

back to speakers